Ovarian cancer
Conditions
Interventions
None listed
Sponsors
Kindai University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Collect blood samples before starting the first treatment in all cases clinically diagnosed with advanced ovarian cancer. In addition, tumor frozen specimens prior to initial drug therapy will be collected. (2) Collect cancer-collected blood samples for all cases diagnosed with platinum-sensitive recurrent ovarian cancer. Furthermore, if the tumor tissue at the time of recurrence is collected by surgery or biopsy, the frozen tumor sample is collected. (3) Collect blood samples before the start of olaparib as maintenance therapy for initial treatment or platinum-sensitive recurrence. (4) Collect blood samples when recurrence or exacerbation is observed after olaparib as maintenance therapy at the first treatment or platinum-sensitive recurrence. If the tumor tissue at the time of recurrence or exacerbation after olaparib administration is collected by surgery or biopsy, a frozen tissue sample is also collected.
Exclusion criteria
Exclusion criteria: Excluded if patient consent has not been obtained for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene mutation before and after olaparib administration | — |
Countries
Japan
Contacts
Public ContactKosuke Murakami
Kindai University Faculty of Medicine Department of Obstetrics & Gynecology
Outcome results
None listed